KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Minority Interest (2017 - 2025)

Historic Minority Interest for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $67.8 million.

  • Amneal Pharmaceuticals' Minority Interest rose 1317.98% to $67.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.8 million, marking a year-over-year increase of 1317.98%. This contributed to the annual value of $65.0 million for FY2024, which is 5734.87% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Minority Interest of $67.8 million as of Q3 2025, which was up 1317.98% from $65.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Minority Interest's 5-year high stood at $72.6 million during Q1 2025, with a 5-year trough of $13.1 million in Q1 2021.
  • Moreover, its 5-year median value for Minority Interest was $32.1 million (2023), whereas its average is $37.4 million.
  • In the last 5 years, Amneal Pharmaceuticals' Minority Interest skyrocketed by 410.73% in 2021 and then surged by 7951.36% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Minority Interest stood at $16.9 million in 2021, then surged by 47.57% to $24.9 million in 2022, then soared by 65.51% to $41.3 million in 2023, then surged by 57.35% to $65.0 million in 2024, then rose by 4.32% to $67.8 million in 2025.
  • Its last three reported values are $67.8 million in Q3 2025, $65.8 million for Q2 2025, and $72.6 million during Q1 2025.